Long lasting synthetic glucagon-like peptide {GLP-1}

Details Long lasting synthetic glucagon-like peptide {GLP-1} Long lasting synthetic glucagon-like peptide {GLP-1}

2005-05-03

2005-05-03

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S324000

Reexamination Certificate

active

06887849

ABSTRACT:
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5612458 (1997-03-01), Hyldig-Nielsen et al.
patent: 5614487 (1997-03-01), Battersby et al.
patent: 5614492 (1997-03-01), Habener
patent: 5958909 (1999-09-01), Habener
patent: 5981488 (1999-11-01), Hoffmann
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6133235 (2000-10-01), Galloway et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6528486 (2003-03-01), Larsen et al.
patent: 20020049153 (2002-04-01), Bridon et al.
patent: WO 9820895 (1998-05-01), None
patent: 0602290 (1994-06-01), None
patent: 0969016 (2000-01-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 9510302 (1995-04-01), None
patent: WO 9808531 (1998-03-01), None
patent: WO 9808871 (1998-03-01), None
patent: WO 9808873 (1998-03-01), None
patent: WO 9843658 (1998-10-01), None
patent: WO 9924074 (1999-05-01), None
patent: WO 9924075 (1999-05-01), None
patent: WO 9929336 (1999-06-01), None
patent: WO 9948536 (1999-09-01), None
patent: WO 0076550 (2000-12-01), None
patent: WO 0076551 (2000-12-01), None
U.S. Appl. No. 10/287,892, filed Nov. 4, 2002, Bridon et al.
U.S. Appl. No. 10/722,733, filed Nov. 25, 2003, Bridon et al.
U.S. Appl. No. 10/723,099, filed Nov. 25, 2003, Bridon et al.
U.S. Appl. No. 09/876,388, filed Jun. 2000, Bridon et al.
U.S. Appl. No. 09/657,332, filed Sep. 2000, Bridon et al.
Proc. Natl. Acad. Sci., 1983, 80, 5485-5489.
Nature, 1983, 302, 716-718.
Endocrinol., 1984, 115, 2176-2181.
Marburg et al. (1996) “Introduction of the Maleimide Function onto Resin-Bound Peptides: A simple, High yield Process Useful for Discriminating among several lysines,” Bioconjugate Chemistry, vol. 7, pp/ 612-616.
Anti-Cancer Drugs, 1997, 8, 677-685.
Siegel et al. (1999) “Biological Activity of GLP-1 analogues with N-terminal modifications,” Regulatory Peptides, vol. 79, issue 23, pp. 93-102.
Ishikawa, E. et al. (Oct. 7, 1978) “Enzyme-Labelling with Maleimides and Its Application to the Immunoassay of Peptide Hormones”Enzyme Labelled Immunoassay of Hormones and Drugs, Walter deGruyter & Co., Berlin, New York: 43-57.

Affiliated with

Also associated with

Rating

Long lasting synthetic glucagon-like peptide {GLP-1} does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long lasting synthetic glucagon-like peptide {GLP-1}, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting synthetic glucagon-like peptide {GLP-1} will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3402692